Impact of mild or moderate chronic kidney disease on the frequency of restenosis: Results from the PRESTO trial

Patricia J.M. Best, Peter B. Berger, Barry R. Davis, Cindy L. Grines, H. Mehrdad Sadeghi, Brent A. Williams, James T. Willerson, Jeffrey R. Granett, David R. Holmes

Research output: Contribution to journalArticlepeer-review

65 Scopus citations


The goal of this study was to determine if restenosis is increased in mild and moderate chronic kidney disease (CKD) patients after percutaneous coronary intervention (PCI). Mortality is increased in CKD after PCI. Restenosis may contribute to increased late mortality. We analyzed 11,187 patients with a creatinine >1.8 mg/dl from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial, grouped by estimated creatinine clearance (CrCl) (<60, 60 to 89, >89 ml/min). The Cox proportional hazards models investigated the association between CrCl group and death, myocardial infarction, and target vessel revascularization (TVR). Generalized estimating equation regression models determined the association between CrCl group and lesion-specific restenosis. At 30 days, there was no difference in myocardial infarction, death, or TVR between the CrCl groups. At nine months, mortality was higher in the lowest CrCl group (2.2%, 1.2%, 0.8%; p > 0.001), which was no longer significant after adjusting for confounding variables. Myocardial infarction and TVR were not different between the groups. In patients undergoing protocol follow-up angiography, restenosis (<50%) was not increased with CKD (32%, 32%, 37%; p = 0.02). Mortality nine months after PCI is mildly increased in mild or moderate CKD patients. However, restenosis is not and does not account for the increased mortality.

Original languageEnglish (US)
Pages (from-to)1786-1791
Number of pages6
JournalJournal of the American College of Cardiology
Issue number9
StatePublished - Nov 2 2004

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Impact of mild or moderate chronic kidney disease on the frequency of restenosis: Results from the PRESTO trial'. Together they form a unique fingerprint.

Cite this